Document Detail

Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab.
MedLine Citation:
PMID:  20357439     Owner:  NLM     Status:  MEDLINE    
Fludarabine is a nucleoside analogue used in the treatment of low-grade lymphoproliferative disorders and in conditioning regimens of non-myeloablative allogeneic stem cell transplantation. This is a relatively safe drug for clinical use but may cause side effects, some of which may be life-threatening. Here a case of severe pulmonary toxicity associated with fludarabine and a possible contribution of rituximab is presented and the literature reviewed.
U Disel; S Paydas; S Yavuz; E Karakoc
Related Documents :
10996239 - Isolated endobronchial atypical mycobacterium in a child: a case report and review of t...
1421719 - Partial anomalous pulmonary venous return showing anomalous venous return to the azygos...
1630989 - Primary pulmonary hypertension and functional hyposplenism.
16291829 - Pulmonary sporothrix schenckii infection in a hiv positive child.
12759629 - Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child wit...
14708559 - Extrapulmonary presentation of asymptomatic pulmonary lymphangioleiomyomatosis.
20628329 - Traumatic pediatric pneumorachis: case report and review of the literature.
22405599 - Emergency testicular sperm extraction after scrotal trauma in a patient with a history...
7467979 - Suprasellar choristoma.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2010-03-30
Journal Detail:
Title:  Chemotherapy     Volume:  56     ISSN:  1421-9794     ISO Abbreviation:  Chemotherapy     Publication Date:  2010  
Date Detail:
Created Date:  2010-05-10     Completed Date:  2010-08-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0144731     Medline TA:  Chemotherapy     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  89-93     Citation Subset:  IM    
Copyright Information:
(c) 2010 S. Karger AG, Basel.
Department of Oncology and Intensive Care Unit, Cukurova University Faculty of Medicine, Adana, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*,  therapeutic use
Lung Diseases / chemically induced*,  physiopathology
Lymphoma, Follicular / drug therapy
Middle Aged
Severity of Illness Index
Vidarabine / administration & dosage,  analogs & derivatives
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/rituximab; 21679-14-1/fludarabine; 5536-17-4/Vidarabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association of a Genetic Variant in the ALOX5AP with Higher Risk of Ischemic Stroke: A Case-Control,...
Next Document:  Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer.